Interferon beta-1b injection site reactions and necroses

Area of Science:

• Neurology
• Pharmacovigilance
• Dermatology

Background:

• Interferon beta-1b is a treatment for multiple sclerosis.
• Adverse events (AEs) are a concern with interferon therapies.
• Injection site reactions and necroses are known AEs.

Purpose of the Study:

• To characterize AEs reported for interferon beta-1b.
• To detail clinical presentation and treatment of AEs.
• To analyze the timing and demographics of AEs.

Main Methods:

• Comprehensive review of FDA adverse event reports.
• Analysis of reports submitted within 30 months of licensure.
• Focus on injection site reactions, injection site necroses, and non-injection site necroses.

Main Results:

• AEs occurred between 1-29 months post-treatment initiation (mean 1 month).
• More severe events (necroses) developed more slowly than reactions.
• Over 85% of AEs presented with 1-2 signs/symptoms.
• A significant female predominance (8.1:1) was noted in reported cases.

Conclusions:

• Interferon beta-1b can cause injection site reactions and necroses.
• AEs have varied onset times, with necroses developing later.
• The observed female predominance warrants further investigation into reporting biases.